{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:23:07Z","timestamp":1771273387965,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","award":["KFS-4990-02-2020"],"award-info":[{"award-number":["KFS-4990-02-2020"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy resistance is still a major problem in the treatment of patients with non-small-cell-lung carcinoma (NSCLC), and novel concepts for the induction of cytotoxicity in NSCLC are highly warranted. Proteotoxicity, the induction of cytotoxicity by targeting the ubiquitin proteasome system, represents an appealing innovative strategy<jats:bold>.<\/jats:bold> The combination of the proteasome inhibitor bortezomib (BTZ) and the proteotoxic stress-inducing HIV drug nelfinavir (NFV) synergistically induces proteotoxicity and shows encouraging preclinical efficacy in NSCLC. The second-generation proteasome inhibitor carfilzomib (CFZ) is superior to BTZ and overcomes BTZ resistance in multiple myeloma patients. Here, we show that CFZ together with NFV is superior to the BTZ\u2009+\u2009NFV combination in inducing endoplasmic reticulum stress and proteotoxicity through the accumulation of excess proteasomal substrate protein in NSCLC in vitro and ex vivo. Interestingly, NFV increases the intracellular availability of CFZ through inhibition of CFZ export from NSCLC cells that express multidrug resistance (MDR) protein. Combining CFZ with NFV may therefore represent a future treatment option for NSCLC, which warrants further investigation.<\/jats:p>","DOI":"10.1038\/s41598-023-31400-6","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T11:03:03Z","timestamp":1679050983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib\/nelfinavir combination in non-small cell lung carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Lenka","family":"Besse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"31400_CR1","first-page":"9","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA: Cancer J. Clin. 64, 9\u201329 (2014).","journal-title":"CA: Cancer J. Clin."},{"key":"31400_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386 (2015).","journal-title":"Int. J. Cancer"},{"key":"31400_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4065\/83.3.355","volume":"83","author":"T Sher","year":"2008","unstructured":"Sher, T., Dy, G. K. & Adjei, A. A. Small cell lung cancer. Mayo Clin. Proc. 83, 355\u2013367 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"31400_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1513\/pats.200809-107LC","volume":"6","author":"GJ Riely","year":"2009","unstructured":"Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, 201\u2013205 (2009).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"31400_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa, C. & Mousa, S. A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 5, 288\u2013300 (2016).","journal-title":"Transl. Lung Cancer Res."},{"key":"31400_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet Lond. Engl. 389, 299\u2013311 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"31400_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","volume":"11","author":"AS Tsao","year":"2016","unstructured":"Tsao, A. S. et al. Scientific advances in lung cancer 2015. J. Thorac. Oncol. 11, 613\u2013638 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"31400_CR8","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1200\/JCO.2015.63.8049","volume":"34","author":"B Melosky","year":"2016","unstructured":"Melosky, B. et al. Pointed progress in second-line advanced non-small-cell lung cancer: The rapidly evolving field of checkpoint inhibition. J. Clin. Oncol. 34, 1676\u20131688 (2016).","journal-title":"J. Clin. Oncol."},{"key":"31400_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/1568009620666200226094000","volume":"20","author":"SO Rohondia","year":"2020","unstructured":"Rohondia, S. O., Ahmed, Z. S. O. & Dou, Q. P. Updated review and perspective on 20S proteasome inhibitors in the treatment of lung cancer. Curr. Cancer Drug Targets 20, 392\u2013409 (2020).","journal-title":"Curr. Cancer Drug Targets"},{"key":"31400_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1172\/JCI0216784","volume":"110","author":"D Ron","year":"2002","unstructured":"Ron, D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110, 1383\u20131388 (2002).","journal-title":"J. Clin. Invest."},{"key":"31400_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/ncb0311-184","volume":"13","author":"I Tabas","year":"2011","unstructured":"Tabas, I. & Ron, D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184\u2013190 (2011).","journal-title":"Nat. Cell Biol."},{"key":"31400_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/17460441.2017.1268596","volume":"12","author":"R Arkwright","year":"2017","unstructured":"Arkwright, R., Pham, T. M., Zonder, J. A. & Dou, Q. P. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opin. Drug Discov. 12, 225\u2013235 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"31400_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V., Richardson, P. G., Hideshima, T. & Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630\u2013639 (2005).","journal-title":"J. Clin. Oncol."},{"key":"31400_CR14","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1038\/bcj.2013.2","volume":"3","author":"M Kraus","year":"2013","unstructured":"Kraus, M., Bader, J., Overkleeft, H. & Driessen, C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 3, e103 (2013).","journal-title":"Blood Cancer J."},{"key":"31400_CR15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","volume":"132","author":"C Driessen","year":"2018","unstructured":"Driessen, C. et al. Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. Blood 132, 2097\u20132100 (2018).","journal-title":"Blood"},{"key":"31400_CR16","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1158\/0008-5472.CAN-20-3323","volume":"81","author":"L Besse","year":"2021","unstructured":"Besse, L. et al. Treatment with HIV-protease inhibitor nelfinavir identifies membrane lipid composition and fluidity as a therapeutic target in advanced multiple myeloma. Cancer Res. 81, 4581\u20134593 (2021).","journal-title":"Cancer Res."},{"key":"31400_CR17","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","volume":"13","author":"JJ Gills","year":"2007","unstructured":"Gills, J. J. et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13, 5183\u20135194 (2007).","journal-title":"Clin. Cancer Res."},{"key":"31400_CR18","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1038\/cddis.2012.87","volume":"3","author":"S Kawabata","year":"2012","unstructured":"Kawabata, S. et al. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis. 3, e353 (2012).","journal-title":"Cell Death Dis."},{"key":"31400_CR19","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","volume":"107","author":"EA Obeng","year":"2006","unstructured":"Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907\u20134916 (2006).","journal-title":"Blood"},{"key":"31400_CR20","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1158\/1535-7163.MCT-07-2375","volume":"7","author":"M Kraus","year":"2008","unstructured":"Kraus, M. et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol. Cancer Ther. 7, 1940\u20131948 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"31400_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bju.14083","volume":"121","author":"D Abt","year":"2018","unstructured":"Abt, D. et al. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int. 121, 600\u2013609 (2018).","journal-title":"BJU Int."},{"key":"31400_CR22","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur, S. et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin. Cancer Res. 17, 2734\u20132743 (2011).","journal-title":"Clin. Cancer Res."},{"key":"31400_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cllc.2020.01.006","volume":"21","author":"SM Arnold","year":"2020","unstructured":"Arnold, S. M. et al. Phase II trial of carfilzomib plus irinotecan in patients with small-cell lung cancer who have progressed on prior platinum-based chemotherapy. Clin. Lung Cancer 21, 357-364.e7 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"31400_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2015.135780","volume":"101","author":"C Driessen","year":"2016","unstructured":"Driessen, C. et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: A phase I trial (SAKK 65\/08). Haematologica 101, 346\u2013355 (2016).","journal-title":"Haematologica"},{"key":"31400_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","volume":"26","author":"A Besse","year":"2019","unstructured":"Besse, A. et al. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem. Biol. 26, 340-351.e3 (2019).","journal-title":"Cell Chem. Biol."},{"key":"31400_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2017.212","volume":"32","author":"A Besse","year":"2018","unstructured":"Besse, A. et al. Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 32, 391\u2013401 (2018).","journal-title":"Leukemia"},{"key":"31400_CR27","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano, G. P. et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 30, 2198\u20132207 (2016).","journal-title":"Leukemia"},{"key":"31400_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00408-003-1029-7","volume":"181","author":"JF Chiou","year":"2003","unstructured":"Chiou, J. F. et al. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 181, 267\u2013273 (2003).","journal-title":"Lung"},{"key":"31400_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fonc.2018.00267","volume":"8","author":"V Sosa Iglesias","year":"2018","unstructured":"Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J. & Vooijs, M. Drug resistance in non-small cell lung cancer: A potential for NOTCH targeting?. Front. Oncol. 8, 267 (2018).","journal-title":"Front. Oncol."},{"key":"31400_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.18632\/oncotarget.268","volume":"2","author":"S Grant","year":"2011","unstructured":"Grant, S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget 2, 284\u2013286 (2011).","journal-title":"Oncotarget"},{"key":"31400_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","volume":"5","author":"LJ Crawford","year":"2011","unstructured":"Crawford, L. J., Walker, B. & Irvine, A. E. Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal. 5, 101\u2013110 (2011).","journal-title":"J. Cell Commun. Signal."},{"key":"31400_CR32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister, S. et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783\u20131792 (2007).","journal-title":"Cancer Res."},{"issue":"Suppl 3","key":"31400_CR33","first-page":"4","volume":"27","author":"TG Martin","year":"2013","unstructured":"Martin, T. G. Peripheral neuropathy experience in patients with relapsed and\/or refractory multiple myeloma treated with carfilzomib. Oncol. Williston Park N 27(Suppl 3), 4\u201310 (2013).","journal-title":"Oncol. Williston Park N"},{"key":"31400_CR34","doi-asserted-by":"publisher","first-page":"e56132","DOI":"10.1371\/journal.pone.0056132","volume":"8","author":"TB Shabaneh","year":"2013","unstructured":"Shabaneh, T. B. et al. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS ONE 8, e56132 (2013).","journal-title":"PLoS ONE"},{"key":"31400_CR35","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/anie.201509092","volume":"55","author":"G de Bruin","year":"2016","unstructured":"de Bruin, G. et al. A set of activity-based probes to visualize human (immuno)proteasome activities. Angew. Chem. Int. Ed Engl. 55, 4199\u20134203 (2016).","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"31400_CR36","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou, T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31400-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T11:13:45Z","timestamp":1679051625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31400"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31400-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4411"}}